Moderna announced the results of a mid-stage trial indicating its COVID-19 vaccine was 96% effective in teens ages 12 to 17 years with no serious adverse effects. The drugmaker said it "is in discussions with regulators about a potential amendment to its regulatory filings."
Moderna: COVID-19 vaccine offers 96% protection in teens
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.